DiaMedica Therapeutics Q3 2024 GAAP EPS $(0.15), Inline
Benzinga Newsdesk 1 year ago
EarningsNews
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate.
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate.